Navigation Links
Transfusing Anemic Cancer Patients Boosts Clot Risk
Date:11/28/2008

"This study shows that transfusions may be no better for patients. We need to be cautious in the use of transfusions and search for ways to reduce our patients' risk of developing blood clots, which are dangerous."

"We need to understand why people who get transfusions are more likely to get blood clots," Dr. Charles Francis, professor of medicine and director of the hemostasis and thrombosis program, said in the news release.

More information

The U.S. Agency for Healthcare Research and Quality has more about blood clots.



-- Robert Preidt



SOURCE: University of Rochester Medical Center, news release, Nov. 24, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

0

GOOD

Page: 1 2

Related medicine news :

1. Drug for anemic cancer patients raises risk of death
2. Novel small molecule therapy shows benefit for anemic patients via hydration of red blood cells
3. ASGE encouraged by drop in colorectal cancer deaths
4. CSHL scientists show how a protein that determines cell polarity prevents breast cancer
5. Report Shows Progress in Fight Against Cancer, but Congress, States Must Step Up Efforts to Reduce Smoking, Lung Cancer
6. Radiation before surgery improves pancreatic cancer outcomes
7. Gene Test Could Predict Colon Cancers Return
8. Cancer incidence and mortality drops among American men and women, according to annual report
9. Annual report to the nation finds declines in cancer incidence and death rates
10. LSUHSCs Dr. Xiao Cheng Wu co-authors annual report to the nation on cancer
11. Weight Boosts Older Womens Breast Cancer Risk
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Transfusing Anemic Cancer Patients Boosts Clot Risk
Transfusing Anemic Cancer Patients Boosts Clot Risk
Breaking Medicine Technology:The Army Awards Follow-On Contract for Autonomous Airway Management to Energid Technologies 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 2China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 3China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 5China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 6China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 7China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 8Steaz Launches Organic Zero Calorie Sparkling Line 59893 1Steaz Launches Organic Zero Calorie Sparkling Line 59893 2Henry Schein to Webcast Third Quarter 2009 Conference Call Wednesday November 4 at 10 A M EST 59891 1Henry Schein to Webcast Third Quarter 2009 Conference Call Wednesday November 4 at 10 A M EST 59891 2Bioidentical Hormones a True Prevention for Breast Cancer 59889 1Bioidentical Hormones a True Prevention for Breast Cancer 59889 2